TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29247148
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg Q2W
Study: 22769235
Drug: Intravenous alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alendronate (ALN) 900 µg every 4 weeks
Study: 22769235
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 35 mg once weekly
Study: 26013711
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) insulin glargine in combination with intravenous (IV) insulin
Study: 26013711
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) insulin (standard care control)
Study: 23353610
Drug: Carbohydrate loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate loading with 18% carbohydrate beverage (375 mL between 9 pm and 12 pm, and 250 mL at 6:30 am)
Study: 21207018
Drug: Isosorbide-SR 40
Normalized name: isosorbide dinitrate 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-SR 40 mg
Study: 19273960
Drug: ASCs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCs treatment
Study: 2905256
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 150 mg once daily
Study: 31010570
Drug: Topical menthol
Normalized name: menthol Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical menthol at different concentrations (liquid and gel formulations)
Study: 25245138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interventions to increase PC and IM
Study: 24093664
Drug: 20 mg/mL
Normalized name: urea 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/mL hyaluronic acid gel (VYC-20L)
Study: 21756794
Drug: Implantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of compound artificial bone of HA-Bone cement
Study: 19131469
Drug: Interactive weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interactive weekly automated telephone self-management support with nurse follow-up (ATSM)
Study: 19131469
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group medical visits with physician and health educator facilitation (GMV)
Study: 16359822
Drug: Estradiol challenge
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol challenge test (estradiolbenzoate 0.04 mg/kg, intramuscular injection)
Study: 15650497
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg-60 mg daily for up to 19 weeks)
Study: 11269568
Drug: A/L/Z combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/L/Z combination tablet after an overnight fast
Study: 11269568
Drug: Abacavir 300
Normalized name: abacavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir 300 mg + Lamivudine 150 mg + Zidovudine 300 mg tablets after an overnight fast
Study: 11269568
Drug: A/L/Z combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/L/Z combination tablet 5 minutes after a standardized high-fat breakfast
Study: 2883988
Drug: H-I 42
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H-I 42 BS 50 mg
Study: 2883988
Drug: H-I 42
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H-I 42 BS 100 mg
Study: 2883988
Drug: H-I 42
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H-I 42 BS 200 mg
Study: 2883988
Drug: H-I 42
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H-I 42 BS 400 mg
Study: 2883988
Drug: H-I 42
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H-I 42 BS 400 mg vs Atenolol 50 mg
Study: 31283891
Drug: Topical CHQ
Normalized name: CHQ
DrugBank: Chloroxine (DB01243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical CHQ 0.03% twice a day with carboxymethylcellulose (CMC) 0.5% three times a day
Study: 31283891
Drug: Topical CMC
Normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical CMC 0.5% three times a day
Study: 28864027
Drug: Tribendimidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 400 mg plus ivermectin 200 μg/kg
Study: 28864027
Drug: Tribendimidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 400 mg plus oxantel pamoate 25 mg/kg
Study: 28864027
Drug: Tribendimidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 400 mg plus placebo (monotherapy)
Study: 28864027
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg plus oxantel pamoate 25 mg/kg
Study: 27755601
Drug: Primary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary prevention using misoprostol (600 mcg)
Study: 24530023
Drug: Intraoperative intracameral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraoperative intracameral injection of 1.2 mg/0.03 mL of triamcinolone acetonide
Study: 24530023
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral prednisolone (1 mg/kg per day for 15 days, tapered over 2 weeks)
Study: 22866670
Drug: autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous PRP injection with rehabilitation programme
Study: 12431940
Drug: Flunkimmune (hypothetical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunkimmune (hypothetical drug)
Study: 2924158
Drug: Hypnotic anesthesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic anesthesia
Study: 518108
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folic acid daily supplement from age 2 months
Study: 31442204
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) in addition to conventional pharmacological treatment with Indacaterol-Glycopyrronium
Study: 31442204
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment with Indacaterol-Glycopyrronium
Study: 28919126
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (2 mSv)
Study: 28919126
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (≤8 mSv)
Study: 8042760
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tramadol (100 mg loading dose, 12 mg/h for 24 h)
Study: 8042760
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tramadol
Study: 8042760
Drug: Repetitive bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive bolus administration (placebo infusion)
Study: 8042760
Drug: Repetitive bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive bolus administration
Study: 26437320
Drug: CC ointment
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC ointment (CCO)
Study: 26437320
Drug: CC or
Normalized name: BD Syringe 10cc Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC or CC digests of collagen type I or III
Study: 23626984
Drug: Zirconia implants
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implants supporting maxillary four-implant overdentures and mandibular three-implant overdentures; 28 implants total (maxilla: 16, mandible: 12)
Study: 31944420
Drug: Zirconia implants
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implants
Study: 18557003
Drug: Disc 'O'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disc 'O' Sit cushions used by 31 students in the treatment group for a 2-week period.
Study: 15159224
Drug: Higher energy-dense
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher energy-dense entrée (7.32 kJ/g) served in the largest portion (900 g)
Study: 15159224
Drug: Lower energy-dense
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower energy-dense entrée (5.23 kJ/g) served in the smallest portion (500 g)
Study: 11454878
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² as a 1-hour infusion every 4 weeks
Study: 11454878
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m²/d for 5 consecutive days every 3 weeks
Study: 9741512
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (digoxin, diuretic, ACEI)
Study: 9741512
Drug: Digoxin and
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin and diuretic therapy
Study: 9741512
Drug: ACEI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI and diuretic therapy
Study: 802630
Drug: Diuretic alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic alone
Study: 3055943
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (50 mg, tid)
Study: 27418571
Drug: Heat-stressed dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stressed dapagliflozin 2.5-mg tablets
Study: 27418571
Drug: Heat-stressed dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stressed dapagliflozin 10-mg tablets
Study: 27418571
Drug: Heat-stressed dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stressed dapagliflozin 2.5-mg tablets (fed state)
Study: 27418571
Drug: Heat-stressed dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stressed dapagliflozin 10-mg tablets (fed state)
Study: 15309493
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material with iodine concentration of 300 mg/ml
Study: 15309493
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material with iodine concentration of 370 mg/ml
Study: 8092097
Drug: Beta-carotene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (60 mg/d)
Study: 2690838
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with hydroxyethyl starch (HAES) and naftidrofuryl
Study: 15475800
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg per day for 60 days
Study: 11762668
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered 1 hour after acetaminophen ingestion
Study: 11762668
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered 2 hours after acetaminophen ingestion
Study: 11762668
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered 3 hours after acetaminophen ingestion
Study: 31738834
Drug: Sirolimus (prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (prednisone ≤0.25 mg/kg/day)
Study: 31738834
Drug: Prednisone (prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (prednisone ≤0.25 mg/kg/day)
Study: 27159069
Drug: ACB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB with 10 mL lidocaine 1%
Study: 20602760
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet
Study: 20602760
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet in fed state
Study: 20602760
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet given three times daily
Study: 10959067
Drug: Tramadol 50-400
Normalized name: tramadol hydrochloride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50-400 mg/day
Study: 11372002
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg/day
Study: 9497506
Drug: Lovastatin 40-80
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40-80 mg at night
Study: 8396100
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg daily for 3 days)
Study: 8396081
Drug: Cloxacillin (dicloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin (dicloxacillin 12.5‐25 mg/kg daily for 7 days or flucloxacillin 250‐2000 mg/day for 7 days)
Study: 30638985
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/day)
Study: 26894424
Drug: Hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic relaxation therapy (5 weekly sessions)
Study: 21246186
Drug: Problem-solving counseling
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving counseling intervention (8 weekly sessions in groups of 8-10 adults)
Study: 17302061
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicinal treatment
Study: 29587297
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin treatment
Study: 7755480
Drug: Captopril, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 75 mg a day (n = 8)
Study: 2472126
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine maleate (100 to 200 mg/d)
Study: 8180714
Drug: Health fair,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health fair, health risk information, follow-up screening, and incentive program (five $100 cash prizes for reducing serum cholesterol levels by 20% or below 5.17 mmol/L)
Study: 762369
Drug: Dihydroergotoxine 6
Normalized name: dihydroergotoxine
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine 6 mg daily
Study: 762369
Drug: Dihydroergotoxine 3
Normalized name: dihydroergotoxine
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine 3 mg daily
Study: 24377218
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy of regulating qi circulation of fu-organ
Study: 24377218
Drug: Shengxue Tongbian
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shengxue Tongbian Capsules
Study: 19139435
Drug: Methotrexate 1
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 1 g/m2 over 24 hours with intrathecal injection and folinic acid rescue at 42 hours (MTX1 arm)
Study: 19139435
Drug: Methotrexate 3
Normalized name: methotrexate 37.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3 g/m2 over 3 hours without intrathecal injection and folinic acid rescue at 24 hours (MTX3 arm)
Study: 19139435
Drug: Methotrexate 1
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 1 g/m2 over 24 hours (MTX1 arm)
Study: 19139435
Drug: Methotrexate 3
Normalized name: methotrexate 37.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3 g/m2 over 3 hours (MTX3 arm)
Study: 17703713
Drug: Bridges intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bridges intervention (Standard Treatment plus Bridges)
Study: 17703713
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment with Attention Control
Study: 15073108
Drug: Ro 09‐4889
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 09‐4889 (1-200 mg)
Study: 15073108
Drug: Ro 09‐4889
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 09‐4889 (20 mg)
Study: 3136639
Drug: Adjunctive enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive enteral supplements
Study: 31841106
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic from Panacea)
Study: 31841106
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (innovator from Astellas)
Study: 31165950
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg)
Study: 28118938
Drug: PIKA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA vaccine classic regimen
Study: 28118938
Drug: PIKA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA vaccine
Study: 24834925
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 or 10 mg/kg every 4 weeks)
Study: 16847400
Drug: R‐/S‐bicalutamide/HP55S 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐/S‐bicalutamide/HP55S 150 mg
Study: 16847400
Drug: R‐bicalutamide/HP55S 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐bicalutamide/HP55S 150 mg
Study: 16847400
Drug: R‐bicalutamide/HP55S 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐bicalutamide/HP55S 450 mg
Study: 9670800
Drug: self‐exposure in
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐exposure in vivo with cognitive therapy
Study: 3198362
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml 0.9% saline/kg body weight (control)
Study: 30822414
Drug: Topical Epigallocatechin-3-Gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Epigallocatechin-3-Gallate (EGCG)
Study: 30822414
Drug: Topical Epigallocatechin-3-Gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Epigallocatechin-3-Gallate (EGCG) by zonal priming
Study: 26328470
Drug: Quercetin (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (162 mg/d from onion skin extract)
Study: 24363694
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 micrograms every 4 hours, up to 6 doses)
Study: 24363694
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter (18 F, inflated with 50 cc of sterile water)
Study: 3769897
Drug: Doxapram (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (3 mg kg‐1)
Study: 3769897
Drug: Almitrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (1 mg kg‐1)
Study: 22575166
Drug: FLU-v low
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLU-v low dose (250 μg) adjuvanted
Study: 22575166
Drug: FLU-v high
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLU-v high dose (500 μg) adjuvanted
Study: 22575166
Drug: FLU-v (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU-v (both doses)
Study: 22575166
Drug: FLU-v (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU-v (all formulations)
Study: 15909196
Drug: CT with
Normalized name: Impact with Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT with IV contrast agent
Study: 15909196
Drug: CT without
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT without IV contrast agent
Study: 6516811
Drug: Control (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.25 ml 0.9% NaCl)
Study: 29410014
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of baricitinib
Study: 29410014
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of baricitinib
Study: 18690839
Drug: All lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: All lipid-lowering agents (LLA) use (statin and non-statin LLA)
Study: 10574477
Drug: Growth hormone,
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone, oral glutamine, and high-carbohydrate-low-fat (HCLF) diet
Study: 1830450
Drug: Enoximone 100
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 100 mg
Study: 1830450
Drug: Enoximone 25
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 25 mg
Study: 31483750
Drug: HPLC-MRM-IDA-EPI analytical
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPLC-MRM-IDA-EPI analytical method for detecting chemotherapy drugs